MedTrace Logo

Cardiac Amyloidosis Screening at Trigger Finger Release

NCT03886155 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2021-12-22

No results posted yet for this study

Summary

The investigators will prospectively evaluate for the presence of amyloid deposits in soft tissue samples obtained from patients undergoing trigger finger release surgery. Patients who have tissue that stains positive for amyloid will be referred to an amyloidosis specialist.

Conditions

  • Amyloidosis
  • Trigger Finger
  • Transthyretin Amyloidosis
  • Primary Amyloidosis of Light Chain Type

Interventions

PROCEDURE

Biopsy

During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Mazen A Hanna, MD · The Cleveland Clinic

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-07-02
Completion
2021-12-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03886155 on ClinicalTrials.gov